Replies to post #789 on Biotech Values

[DewDiligence]

Re: AdPEDF dosing:

isolution et al: Do you have any idea why the dose range in the ongoing AdPEDF trial is so large compared to the dose ranges typically used for other drug candidates? The highest AdPEDF dose is approximately 3,000 times (3.5 base-10 logs) the lowest dose! T.i.a. Dew

[DewDiligence]

Update on GNVC’s AdPEDF from SG Cowen webcast:

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=GNVC&script=1100&layout=-6#100342

The information is essentially the same as what was GNVC reported two months ago (#msg-2086311): GNVC is wrapping up their phase-1 dose-escalating AMD trial and is planning to start a placebo-controlled phase-2 trial with 50-60 patients in mid-2004. (Curiously, the trial size was given as 50-70 at the prior CC.) Some AdPEDF data may be released at ARVO next month.

GNVC sounds very confident about the AdPEDF program in AMD, although the treatment approach still strikes me as high-risk. I will be very interested to see the clinical data.